Aurobindo’s Unit III, which is located at Bachupally in Medchal Malkajgiri district, was inspected by USFDA from July 14 to 21 this year. The company informed the bourses that the observations are procedural in nature and it would keep the stock exchanges if there was any material information relating to the matter in future.
